- Home
- FNF vs RPRX Comparison
FNF vs RPRX Comparison
Compare FNF & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNF | RPRX |
|---|---|---|
| Founded | 1847 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 16.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FNF | RPRX |
|---|---|---|
| Price | $53.66 | $40.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $70.00 | $45.75 |
| AVG Volume (30 Days) | 1.4M | ★ 3.7M |
| Earning Date | 02-19-2026 | 02-10-2026 |
| Dividend Yield | ★ 3.79% | 2.19% |
| EPS Growth | ★ 55.69 | N/A |
| EPS | ★ 4.29 | 1.75 |
| Revenue | ★ $14,060,000,000.00 | $2,349,844,000.00 |
| Revenue This Year | $3.97 | $37.66 |
| Revenue Next Year | $9.59 | $2.34 |
| P/E Ratio | ★ $12.80 | $22.93 |
| Revenue Growth | ★ 3.92 | 3.70 |
| 52 Week Low | $50.61 | $27.47 |
| 52 Week High | $66.72 | $41.70 |
Technical Indicators
Market Signals| Indicator | FNF | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.55 | 58.63 |
| Support Level | $54.90 | $39.98 |
| Resistance Level | $57.01 | $41.70 |
| Average True Range (ATR) | 1.19 | 0.74 |
| MACD | -0.05 | 0.14 |
| Stochastic Oscillator | 24.27 | 58.94 |
Price Performance
Historical ComparisonAbout FNF FNF Group of Fidelity National Financial Inc.
Fidelity National Financial Inc is a provider of (i) title insurance, escrow and other title-related services, including trust activities, trustee sales guarantees, recordings and reconveyances and home warranty and (ii) transaction services to the real estate and mortgage industries. It operates in three segments: Title, F&G, Corporate and Other. The title segment that derives the majority of revenue consists of the operations of title insurance underwriters and related businesses, which provide title insurance and escrow and other title-related services including trust activities, trustee sales guarantees, and home warranty products. Substantially all of the company's revenue is generated in the United States.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.